TitleAssistant Professor
InstitutionMD Anderson
DepartmentGenitourinary Medical Oncology
Address1155 Pressler St
Houston TX 77030-3721
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Karam JA, Msaouel P, Haymaker CL, Matin SF, Campbell MT, Zurita AJ, Shah AY, Wistuba II, Marmonti E, Duose DY, Parra ER, Soto LMS, Laberiano-Fernandez C, Lozano M, Abraham A, Hallin M, Chin CD, Olson P, Der-Torossian H, Yan X, Tannir NM, Wood CG. Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma. Nat Commun. 2023 May 10; 14(1):2684. PMID: 37164948; PMCID: PMC10172300.
    2. Alhalabi O, Groisberg R, Zinner R, Hahn AW, Naing A, Zhang S, Tsimberidou AM, Rodon J, Fu S, Yap TA, Hong DS, Sun M, Jiang Y, Pant S, Shah AY, Zurita A, Tannir NM, Vikram R, Roszik J, Meric-Bernstam F, Subbiah V. Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies. NPJ Precis Oncol. 2023 Apr 18; 7(1):37. PMID: 37072571; PMCID: PMC10113233.
    3. Hahn AW, Kotecha RR, Viscuse PV, Pieretti AC, Wiele AJ, Jonasch E, Lee CH, Gao J, Zurita AJ, Shah AY, Campbell MT, Sharma P, Motzer RJ, Russo P, Wood CG, Tannir NM, Voss MH, Karam JA, Hakimi AA, Msaouel P. Cytoreductive Nephrectomy for Patients with Metastatic Sarcomatoid and/or Rhabdoid Renal Cell Carcinoma Treated with Immune Checkpoint Therapy. Eur Urol Focus. 2023 Feb 28. PMID: 36863962.
      Citations:    Fields:    
    4. Saji A, Chopra M, Jacob J, Altan M, Alhalabi O, Shah AY, Qiao W, Wang Y, Thomas A. Implementing an immunotherapy toxicity (IOTOX) GI service improves outcomes in patients with immune-mediated diarrhea and colitis. J Cancer Res Clin Oncol. 2022 Dec 31. PMID: 36585982.
      Citations: 1     Fields:    
    5. Labbate CV, Hensley PJ, Miest TS, Qiao W, Adibi M, Shah AY, Chery L, Papadopoulos J, Siefker-Radtke AO, Gao J, Guo CC, Czerniak BA, Navai N, Kamat AM, Dinney CP, Campbell MT, Matin SF. Longitudinal GFR trends after neoadjuvant chemotherapy prior to nephroureterectomy for upper tract urothelial carcinoma. Urol Oncol. 2022 10; 40(10):454.e17-454.e23. PMID: 35961847.
    6. Moore JA, Lehner MJ, Anfossi S, Datar S, Tidwell RS, Campbell M, Shah AY, Ward JF, Karam JA, Wood CG, Pisters LL, Calin GA, Tu SM. Predictive capacity of a miRNA panel in identifying teratoma in post-chemotherapy consolidation surgeries. BJUI Compass. 2023 Jan; 4(1):81-87. PMID: 36569509; PMCID: PMC9766861.
    7. Sherry AD, Bathala TK, Liu S, Fellman BM, Chun SG, Jasani N, Guadagnolo BA, Jhingran A, Reddy JP, Corn PG, Shah AY, Kaiser KW, Ghia AJ, Gomez DR, Tang C. Definitive Local Consolidative Therapy for Oligometastatic Solid Tumors: Results From the Lead-in Phase of the Randomized Basket Trial EXTEND. Int J Radiat Oncol Biol Phys. 2022 12 01; 114(5):910-918. PMID: 35691448.
      Citations:    Fields:    
    8. Motzer RJ, Powles T, Burotto M, Escudier B, Shah AY, Hamzaj A, Porta C, Hocking CM, Kessler ER, Gurney H, Tomita Y, Zhang J, Simsek B, Scheffold C, Apolo AB, Choueiri TK, Bourlon MT, Su?rez C, Bedke J. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. Lancet Oncol. 2022 07; 23(7):888-898. PMID: 35688173.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    9. Msaouel P, Goswami S, Thall PF, Wang X, Yuan Y, Jonasch E, Gao J, Campbell MT, Shah AY, Corn PG, Tam AL, Ahrar K, Rao P, Sircar K, Cohen L, Basu S, Duan F, Jindal S, Zhang Y, Chen H, Yadav SS, Shazer R, Der-Torossian H, Allison JP, Sharma P, Tannir NM. A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy. Sci Transl Med. 2022 04 20; 14(641):eabm6420. PMID: 35442707.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    10. Daher M, Varghese J, Gruschkus SK, Jimenez C, Waguespack SG, Bedrose S, Altameemi L, Bazerbashi H, Naing A, Subaiah V, Campbell MT, Shah AY, Zhang M, Sheth RA, Karam JA, Wood CG, Perrier ND, Graham PH, Lee JE, Habra MA. Temporal Trends in Outcomes in Patients With Adrenocortical Carcinoma: A Multidisciplinary Referral-center Experience. J Clin Endocrinol Metab. 2022 04 19; 107(5):1239-1246. PMID: 35092681; PMCID: PMC9016449.
      Citations:    Fields:    Translation:Humans
    11. Kim ST, Chu Y, Misoi M, Suarez-Almazor ME, Tayar JH, Lu H, Buni M, Kramer J, Rodriguez E, Hussain Z, Neelapu SS, Wang J, Shah AY, Tannir NM, Campbell MT, Gibbons DL, Cascone T, Lu C, Blumenschein GR, Altan M, Lim B, Valero V, Loghin ME, Tu J, Westin SN, Naing A, Garcia-Manero G, Abdel-Wahab N, Tawbi HA, Hwu P, Oliva ICG, Davies MA, Patel SP, Zou J, Futreal A, Diab A, Wang L, Nurieva R. Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nat Commun. 2022 04 12; 13(1):1970. PMID: 35413951; PMCID: PMC9005525.
      Citations: 1     Fields:    Translation:HumansCells
    12. Alhalabi O, Chen J, Zhang Y, Lu Y, Wang Q, Ramachandran S, Tidwell RS, Han G, Yan X, Meng J, Wang R, Hoang AG, Wang WL, Song J, Lopez L, Andreev-Drakhlin A, Siefker-Radtke A, Zhang X, Benedict WF, Shah AY, Wang J, Msaouel P, Zhang M, Guo CC, Czerniak B, Behrens C, Soto L, Papadimitrakopoulou V, Lewis J, Rinsurongkawong W, Rinsurongkawong V, Lee J, Roth J, Swisher S, Wistuba I, Heymach J, Wang J, Campbell MT, Efstathiou E, Titus M, Logothetis CJ, Ho TH, Zhang J, Wang L, Gao J. MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers. Nat Commun. 2022 04 04; 13(1):1797. PMID: 35379845; PMCID: PMC8980015.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    13. Moore JA, Slack RS, Lehner MJ, Campbell MT, Shah AY, Zhang M, Guo CC, Ward JF, Karam JA, Wood CG, Pisters LL, Tu SM. Very Late Recurrence in Germ Cell Tumor of the Testis: Lessons and Implications. Cancers (Basel). 2022 Feb 23; 14(5). PMID: 35267435; PMCID: PMC8909729.
    14. Shapiro DD, Soeung M, Perelli L, Dondossola E, Surasi DS, Tripathi DN, Bertocchio JP, Carbone F, Starbuck MW, Van Alstine ML, Rao P, Katz MHG, Parker NH, Shah AY, Carugo A, Heffernan TP, Schadler KL, Logothetis C, Walker CL, Wood CG, Karam JA, Draetta GF, Tannir NM, Genovese G, Msaouel P. Association of High-Intensity Exercise with Renal Medullary Carcinoma in Individuals with Sickle Cell Trait: Clinical Observations and Experimental Animal Studies. Cancers (Basel). 2021 Nov 30; 13(23). PMID: 34885132; PMCID: PMC8656882.
      Citations: 2     
    15. Alhalabi O, Zhu Y, Hamza A, Qiao W, Lin Y, Wang RM, Shah AY, Campbell MT, Holla V, Kamat A, Wang WL, Wang J, Chen J, Meng J, Zhang M, Bondaruk J, Titus M, Genovese G, Czerniak BA, Shaw KR, Meric-Bernstam F, Guo CC, Logothetis CJ, Siefker-Radtke A, Msaouel P, Wang L, Liu J, Gao J. Integrative Clinical and Genomic Characterization of MTAP-deficient Metastatic Urothelial Cancer. Eur Urol Oncol. 2023 04; 6(2):228-232. PMID: 34789422; PMCID: PMC9106763.
      Citations: 4     Fields:    
    16. Campbell MT, Matin SF, Tam AL, Sheth RA, Ahrar K, Tidwell RS, Rao P, Karam JA, Wood CG, Tannir NM, Jonasch E, Gao J, Zurita AJ, Shah AY, Jindal S, Duan F, Basu S, Chen H, Espejo AB, Allison JP, Yadav SS, Sharma P. Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma. Nat Commun. 2021 11 04; 12(1):6375. PMID: 34737281; PMCID: PMC8569213.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    17. Tang C, Msaouel P, Hara K, Choi H, Le V, Shah AY, Wang J, Jonasch E, Choi S, Nguyen QN, Das P, Prajapati S, Yu Z, Khan K, Powell S, Murthy R, Sircar K, Tannir NM. Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial. Lancet Oncol. 2021 12; 22(12):1732-1739. PMID: 34717797.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    18. Alhalabi O, Campbell MT, Xiao L, Adriazola AC, Wilson NR, Siefker-Radtke AO, Corn PG, Zurita A, Jonasch E, Gao J, Adibi M, Kamat AM, Navai N, Pisters LL, Dinney C, Matin SF, Shah AY. Multimodal kidney-preserving approach in localised and locally advanced high-risk upper tract urothelial carcinoma. BJUI Compass. 2022 Jan; 3(1):37-44. PMID: 35475152; PMCID: PMC8988842.
      Citations: 2     
    19. Wilson NR, Wiele AJ, Surasi DS, Rao P, Sircar K, Tamboli P, Shah AY, Genovese G, Karam JA, Wood CG, Tannir NM, Msaouel P. Efficacy and safety of gemcitabine plus doxorubicin in patients with renal medullary carcinoma. Clin Genitourin Cancer. 2021 12; 19(6):e401-e408. PMID: 34625389.
      Citations: 1     Fields:    Translation:Humans
    20. Msaouel P, Oromendia C, Siefker-Radtke AO, Tannir NM, Subudhi SK, Gao J, Wang Y, Siddiqui BA, Shah AY, Aparicio AM, Campbell MT, Zurita AJ, Shaw LK, Lopez LP, McCord H, Chakraborty SN, Perales J, Lu C, Van Alstine ML, Elashoff M, Logothetis C. Evaluation of Technology-Enabled Monitoring of Patient-Reported Outcomes to Detect and Treat Toxic Effects Linked to Immune Checkpoint Inhibitors. JAMA Netw Open. 2021 08 02; 4(8):e2122998. PMID: 34459906; PMCID: PMC8406081.
      Citations: 2     Fields:    Translation:HumansPHPublic Health
    21. De B, Venkatesan AM, Msaouel P, Ghia AJ, Li J, Yeboa DN, Nguyen QN, Bishop AJ, Jonasch E, Shah AY, Campbell MT, Wang J, Zurita-Saavedra AJ, Karam JA, Wood CG, Matin SF, Tannir NM, Tang C. Definitive radiotherapy for extracranial oligoprogressive metastatic renal cell carcinoma as a strategy to defer systemic therapy escalation. BJU Int. 2022 05; 129(5):610-620. PMID: 34228889; PMCID: PMC10097479.
      Citations: 1     Fields:    Translation:Humans
    22. Lee CH, Shah AY, Rasco D, Rao A, Taylor MH, Di Simone C, Hsieh JJ, Shaffer DR, Cohn AL, Vogelzang NJ, Bilen MA, Gunnestad Ribe S, Goksel M, Richards D, Sweis RF, Courtright J, Jain S, Wu J, Schmidt EV, Perini RF, Kubiak P, Okpara CE, Smith AD, Motzer RJ, Pinto A, Girones Sarrio R, Tenn?e ?K, Heinrich D. Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study. Lancet Oncol. 2021 07; 22(7):946-958. PMID: 34143969; PMCID: PMC8316679.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    23. Andreev-Drakhlin AY, Egoryan G, Shah AY, Msaouel P, Alhalabi O, Gao J. The evolving treatment landscape of advanced urothelial carcinoma. Curr Opin Oncol. 2021 05 01; 33(3):221-230. PMID: 33818541.
      Citations: 2     Fields:    Translation:Humans
    24. Wiele AJ, Surasi DS, Rao P, Sircar K, Su X, Bathala TK, Shah AY, Jonasch E, Cataldo VD, Genovese G, Karam JA, Wood CG, Tannir NM, Msaouel P. Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma. Cancers (Basel). 2021 Apr 30; 13(9). PMID: 33946504; PMCID: PMC8124338.
      Citations: 2     
    25. Wiele AJ, Bathala TK, Hahn AW, Xiao L, Duran M, Ross JA, Jonasch E, Shah AY, Campbell MT, Msaouel P, Tannir NM. Lenvatinib with or Without Everolimus in Patients with Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapies. Oncologist. 2021 06; 26(6):476-482. PMID: 33792094; PMCID: PMC8176993.
      Citations: 4     Fields:    Translation:Humans
    26. Alhalabi O, Hasanov E, Wilson NR, Araujo J, Wang J, Campbell MT, Goswami S, Shah AY, Gao J, Msaouel P, Tannir NM. Outcomes of patients with intermediate-risk or poor-risk metastatic renal cell carcinoma who received their first cycle of nivolumab and ipilimumab in the hospital because of symptomatic disease: The MD Anderson Cancer Center experience. Int J Cancer. 2021 07 15; 149(2):387-393. PMID: 33739450.
      Citations: 2     Fields:    Translation:Humans
    27. Viscuse PV, Marques-Piubelli ML, Heberton MM, Parra ER, Shah AY, Siefker-Radtke A, Gao J, Goswami S, Ivan D, Curry JL, Campbell MT. Case Report: Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Case Series on the Clinical and Histopathologic Spectrum of Adverse Cutaneous Reactions From Fatal Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis to Dermal Hypersensitivity Reaction. Front Oncol. 2021; 11:621591. PMID: 33747934; PMCID: PMC7970171.
      Citations: 4     
    28. CheckMate 9ER Investigators, Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B, Oyervides Ju?rez VM, Hsieh JJ, Basso U, Shah AY, Su?rez C, Hamzaj A, Goh JC, Barrios C, Richardet M, Porta C, Kowalyszyn R, Feregrino JP, Zolnierek J, Pook D, Kessler ER, Tomita Y, Mizuno R, Bedke J, Zhang J, Maurer MA, Simsek B, Ejzykowicz F, Schwab GM, Apolo AB, Motzer RJ. Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2021 03 04; 384(9):829-841. PMID: 33657295; PMCID: PMC8436591.
      Citations: 173     Fields:    Translation:HumansCTClinical Trials
    29. Ravindranathan D, Alhalabi O, Rafei H, Shah AY, Bilen MA. Landscape of Immunotherapy in Genitourinary Malignancies. Adv Exp Med Biol. 2021; 1342:143-192. PMID: 34972965.
      Citations:    Fields:    Translation:Humans
    30. Alhalabi O, Hahn AW, Msaouel P, Andreev-Drakhlin AY, Meric-Bernstam F, Naing A, Piha-Paul S, Filip J, Pant S, Yap TA, Hong DS, Fu S, Karp D, Campbell E, Le H, Campbell MT, Shah AY, Tannir NM, Siefker-Radtke AO, Gao J, Roszik J, Subbiah V. Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes. Mol Cancer Res. 2021 03; 19(3):395-402. PMID: 33323389.
      Citations: 1     Fields:    Translation:Humans
    31. Economides MP, Shah AY, Jimenez C, Habra MA, Desai M, Campbell MT. A Durable Response With the Combination of Nivolumab and Cabozantinib in a Patient With Metastatic Paraganglioma: A Case Report and Review of the Current Literature. Front Endocrinol (Lausanne). 2020; 11:594264. PMID: 33329398; PMCID: PMC7731902.
      Citations: 1     Fields:    Translation:Humans
    32. McGregor BA, Campbell MT, Xie W, Farah S, Bilen MA, Schmidt AL, Sonpavde GP, Kilbridge KL, Choudhury AD, Mortazavi A, Shah AY, Venkatesan AM, Bubley GJ, Siefker-Radtke AO, McKay RR, Choueiri TK. Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies. Cancer. 2021 03 15; 127(6):840-849. PMID: 33216356.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    33. Chahoud J, Msaouel P, Ross JA, McCormick BZ, Bathala TK, Gao J, Horn R, Xiao L, Sircar K, Campbell MT, Shah AY, Goswami S, Zurita AJ, Jonasch E, Matin SF, Wood CG, Karam JA, Sharma P, Tannir NM. Outcomes of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation to immune checkpoint inhibitors. Urol Oncol. 2021 02; 39(2):134.e9-134.e16. PMID: 33187886.
      Citations: 1     Fields:    Translation:Humans
    34. Gao J, Navai N, Alhalabi O, Siefker-Radtke A, Campbell MT, Tidwell RS, Guo CC, Kamat AM, Matin SF, Araujo JC, Shah AY, Msaouel P, Corn P, Wang J, Papadopoulos JN, Yadav SS, Blando JM, Duan F, Basu S, Liu W, Shen Y, Zhang Y, Macaluso MD, Wang Y, Chen J, Zhang J, Futreal A, Dinney C, Allison JP, Goswami S, Sharma P. Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nat Med. 2020 12; 26(12):1845-1851. PMID: 33046869.
      Citations: 41     Fields:    Translation:HumansCTClinical Trials
    35. Alhalabi O, Rafei H, Bilen MA, Shah AY. Current Landscape of Immunotherapy in Genitourinary Malignancies. Adv Exp Med Biol. 2020; 1244:107-147. PMID: 32301013.
      Citations:    Fields:    Translation:Humans
    36. Graham J, Shah AY, Wells JC, McKay RR, Vaishampayan U, Hansen A, Donskov F, Bjarnason GA, Beuselinck B, De Velasco G, Iafolla M, Duh MS, Huynh L, Chang R, Zanotti G, Ramaswamy K, Choueiri TK, Tannir NM, Heng DYC. Outcomes of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy After Immuno-oncology Checkpoint Inhibitors. Eur Urol Oncol. 2021 02; 4(1):102-111. PMID: 31786162.
      Citations: 7     Fields:    Translation:Humans
    37. Yeboa DN, Shah AY. Managing Perplexing Intracranial Lesions. Int J Radiat Oncol Biol Phys. 2019 10 01; 105(2):244. PMID: 31492380.
      Citations:    Fields:    Translation:Humans
    38. Chahoud J, Msaouel P, Campbell MT, Bathala T, Xiao L, Gao J, Zurita AJ, Shah AY, Jonasch E, Sharma P, Tannir NM. Nivolumab for the Treatment of Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma (nccRCC): A Single-Institutional Experience and Literature Meta-Analysis. Oncologist. 2020 03; 25(3):252-258. PMID: 32162795; PMCID: PMC7066696.
      Citations: 23     Fields:    Translation:Humans
    39. Shah AY, Kotecha RR, Lemke EA, Chandramohan A, Chaim JL, Msaouel P, Xiao L, Gao J, Campbell MT, Zurita AJ, Wang J, Corn PG, Jonasch E, Motzer RJ, Sharma P, Voss MH, Tannir NM. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors. Eur J Cancer. 2019 06; 114:67-75. PMID: 31075726; PMCID: PMC7537491.
      Citations: 27     Fields:    Translation:Humans
    40. Lemke EA, Shah AY, Campbell M, Tannir NM. Real-World Experience With Cabozantinib in Metastatic Clear Cell Renal Cell Carcinoma: A Retrospective Analysis. J Adv Pract Oncol. 2019 May-Jun; 10(4):333-339. PMID: 33343982; PMCID: PMC7520741.
      Citations: 1     
    41. Alhalabi O, Shah AY, Lemke EA, Gao J. Current and Future Landscape of Immune Checkpoint Inhibitors in Urothelial Cancer. Oncology (Williston Park). 2019 Jan 17; 33(1):11-8. PMID: 30731013.
      Citations: 4     Fields:    Translation:Humans
    42. Campbell MT, Bilen MA, Shah AY, Lemke E, Jonasch E, Venkatesan AM, Altinmakas E, Duran C, Msaouel P, Tannir NM. Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis. Eur J Cancer. 2018 11; 104:188-194. PMID: 30380460.
      Citations: 20     Fields:    Translation:Humans
    43. Lemke EA, Shah AY. Management of Advanced Bladder Cancer: An Update. J Adv Pract Oncol. 2018 May-Jun; 9(4):410-416. PMID: 30719393; PMCID: PMC6347090.
      Citations: 7     
    44. Shah AY, Gao J, Siefker-Radtke AO. Five new therapies or just one new treatment? A critical look at immune checkpoint inhibition in urothelial cancer. Immunotherapy. 2017 09; 9(10):781-784. PMID: 28877627.
      Citations: 2     Fields:    Translation:Humans
    45. Shah AY, Tannir NM. Editorial Comment. Urology. 2017 11; 109:132. PMID: 28867144.
      Citations:    Fields:    
    46. Maiti A, Nemati-Shafaee M, Msaouel P, Pagliaro LC, Jonasch E, Tannir NM, Shah AY. Phase 2 Trial of Capecitabine, Gemcitabine, and Bevacizumab in Sarcomatoid Renal-Cell Carcinoma. Clin Genitourin Cancer. 2017 Aug 10. PMID: 28870517; PMCID: PMC5809227.
      Citations: 7     Fields:    
    47. Campbell MT, Shah AY, Matin SF, Siefker-Radtke AO. Optimizing management of upper tract urothelial carcinoma. Urol Oncol. 2017 07; 35(7):492-498. PMID: 28579283.
      Citations: 3     Fields:    Translation:Humans
    48. Joseph RW, Shah AY, Tannir NM, Malouf GG. Non-clear cell renal cell carcinomas: biological insights and therapeutic challenges and opportunities. Clin Adv Hematol Oncol. 2017 May; 15(5):409-418. PMID: 28591094.
      Citations: 5     Fields:    Translation:Humans
    49. Shah AY, Karam JA, Rao P, Lim ZD, Jonasch E, Xiao L, Gao J, Vaishampayan UN, Heng DY, Plimack ER, Guancial EA, Fung C, Lowas SR, Tamboli P, Sircar K, Matin SF, Kimryn Rathmell W, Wood CG, Tannir NM, Malouf GG. Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study. BJU Int. 2017 12; 120(6):782-792. PMID: 27860149; PMCID: PMC6857178.
      Citations: 22     Fields:    Translation:Humans
    50. Shah AY, Karam JA, Lim ZD, Ng CS, Tannir NM. Clinical and pathological complete remission in a patient with metastatic renal cell carcinoma (mRCC) treated with sunitinib: Is mRCC curable with targeted therapy? Urol Case Rep. 2015 Mar 01; 3(2):18-20. PMID: 26120560; PMCID: PMC4477704.
      Citations: 2     
    51. Clinical and pathological complete remission in a patient with metastatic renal cell carcinoma (mrcc) treated with sunitinib. Urology Case Reports. 3:18-20.
    52. Management and outcomes of patients with renal medullary carcinoma. BJU International.
    SHAH's Networks
    Click the
    buttons for more information and interactive visualizations!
    Concepts (113)
    Co-Authors (101)
    Similar People (60)
    Same Department Expand Description